共 50 条
- [1] Vericiguat reduced a composite of CV death or HF hospitalization in patients with HF and reduced LVEFANNALS OF INTERNAL MEDICINE, 2020, 173 (06) : JC30 - JC30Averbuch, TaubenVan Spall, Harriette G. C.
- [2] In heart failure, adding empagliflozin to medical therapy reduced a composite of CV death or HF hospitalizationANNALS OF INTERNAL MEDICINE, 2020, 173 (10) : JC51 - JC51Palaskas, Nicolas L.Deswal, Anita
- [4] In HF, MRAs reduced HF hospitalization or CV death regardless of ejection fractionANNALS OF INTERNAL MEDICINE, 2025, 178 (01) : JC3 - JC3Donato, Anthony A.Ameen, Muhammad
- [5] In HF with LVEF ≤ 42.5%, sacubitril-valsartan vs RAS inhibitors reduced a composite of CV death or HF hospitalizationANNALS OF INTERNAL MEDICINE, 2020, 172 (12) : JC65 - JC65Sen, SounokNewby, L. Kristin
- [6] In HFpEF, the benefit of empagliflozin on a composite of CV death or HF hospitalization at 26 mo did not vary by diabetes statusANNALS OF INTERNAL MEDICINE, 2022, 175 (10) : JC111 - JC111Fudim, MaratVan Spall, Harriette G. C.
- [7] In HFpEF, semaglutide reduced a composite of worsening HF or CV deathANNALS OF INTERNAL MEDICINE, 2025, 178 (01) : JC4 - JC4Lam, Steven Ho ManLip, Gregory Y. H.
- [8] Dapagliflozin reduced worsening HF or CV death in HF with reduced ejection fractionANNALS OF INTERNAL MEDICINE, 2020, 172 (04) : JC16 - JC16Sullivan, KristenVan Spall, Harriette G. C.
- [9] In adults with AMI who are at risk for HF, empagliflozin did not reduce a composite of first HF hospitalization or all-cause death at 18 moANNALS OF INTERNAL MEDICINE, 2024, 177 (07) : JC74 - JC74Keppel, StormyBorzak, Steven
- [10] In HF, with or without PAD, dapagliflozin reduced a composite of worsening HF or CV death and did not increase amputationsANNALS OF INTERNAL MEDICINE, 2023, 176 (09) : JC99 - JC99Mukherjee, Debabrata